For #WorldHepatitisDay we stand together 🩺 At A‑TANGO, we aim to transform healthcare for people with #LiverDisease, including those living with #cirrhosis and #ACLF, putting #patients first ☺️ Every person deserves timely, effective, and #stigma‑free support 💪 @europeliver.bsky.social @who.int

What an inspiring 9th Steering Committee Meeting! It was lovely to meet fellow liver-health enthusiasts & clinical investigators who recently joined the #GTAK Study. Let's include as many #ACLF patients in the study as possible.💉😊 #AlcoholicHepatitis @europeliver.bsky.social @easlnews.bsky.social

Join this exciting event! Don't miss our #OpenInnovation event, uniting experts in #DrugDevelopment, #bioinformatics, and #hepatology. Connect with researchers, industry professionals, and investors to share insights & explore collaboration opportunities! 🚀 Register now: inevent.uk/en/Crowdheli...

📣 Secure your spot now 📣: inevent.uk/en/Crowdheli... Check out our upcoming (online) A-TANGO #LiverHealth Helix Event! 🟣 Industrial Perspective on #DrugDevelopment Challenges for #ClinicalTrials 🗓️ 04 June 2025 🕙 Begin: 10 am BST #ClinicalResearch @rajivjalan.bsky.social @easlnews.bsky.social

At #EASL2025, ELPA President Marko Korenjak presented 3 EU projects: A-TANGO, LIVER AIM & THRIVE. At the Layperson Events, science met real stories — patients at the center of innovation, action & hope. @liveraim.bsky.social @A-TANGO @THRIVE @korenjak.bsky.social @ninadonner.bsky.social

✅ How to reach a #consensus in science 🧬: Clinic director Frank Tacke (Charité) trains future #hepatology leaders on the #DelphiMethod, a reliable forecasting method using multiple rounds of questionnaires for an expert panel to reach a mutual agreement. 🗓️ What a fun #workshop at #EASLCongress 2025

🧠 SAT-210 – #EASL2025 New tool alert! The #mHEST scale brings clarity to grading hepatic #encephalopathy in trials & clinics. A big step for #cirrhosis care. Kudos to Prof. @rajivjalan.bsky.social & his team! #LiverHealth #HE #ClinicalResearch

🧪 SAT-209 – #EASL2025 MNK6106 vs. rifaximin to treat #HepaticEncephalopathy - new Phase 2a data from Prof. @rajivjalan.bsky.social (UCL) explores safety, PK & ammonia-lowering potential. HE treatment innovation in motion! #Cirrhosis

👏 Fantastic job by Annarein Kerbert, LUMC, + Julian Pohl, Charité, at today's #networking session at #EASLCongress 👉 Is #alcohol-related #hepatitis in ACLF its own beast? 👉 Is systemic #inflammation the puppet master pulling #ACLF’s strings in booze-related hepatitis? Chair @rajivjalan.bsky.social

👑 The crown belongs to Julian Pohl for one of this year's TOP #Posters at #EASLCongress - Wow! 👏 🥳 TOP-217-YI 🥳 Pathophysiological basis of #ACLF triggered by #alcohol-related #hepatitis or #infection using circulating biomarkers of #inflammation, circulatory dysfunction & #albumin modifications

Today’s #readoftheweek📚 highlights the presence of inflammation and bacterial products in the systemic circulation in patients with compensated #cirrhosis and clinically significant portal hypertension. Read here this JHEP Reports article: www.jhep-reports.eu/article/S258... #LiverSky

🥳 SATURDAY 🥳 If you didn't party too hard on Friday eve: Step by, say hi and listen to exciting talks by Annarein Kerbert, LUMC & Julian Pohl, Charité #AlcoholicHepatitis #cirrhosis #ACLF #inflammation @rajivjalan.bsky.social @medblab.bsky.social @decision4liver.bsky.social @easlnews.bsky.social

Big crowd at the #ACLF & Critical Illness #PosterTour at #EASLCongress: FRI-197 The AMMON-OHE model predicts #liver-related #complications in #outpatients with #cirrhosis: A prospective cohort study of the #AMMON consortium Crucial for understanding the disease progression! @rajivjalan.bsky.social

🌟 POSTER THU-182 by Supachaya S. (UCL, @rajivjalan.bsky.social) featured in a #PosterTour at #EASLCongress! 👏 👉 Transcriptomic & metabolic insights into #hyperammonemia: The complementary therapeutic roles of #TLR4 inhibitor (#TAK242) + ornithine phenylacetate 👍 In A-TANGO, we use #TAK242 + G-CSF

🎬 Summary #movie of A-TANGO's Investigator & Industry Session 🥂 at #EASLCongress. Big thanks to Yaqrit for sponsoring this inspiring event. Let's roll up our sleeves now to start the #GTAK trial in the UK, and hopefully also in India + Germany & other EU countries 🩺 ☺️! #ACLF #cirrhosis #LiverFailure

💲💰 Wake up your inner #entrepreneur, found your own start-up #company #business, and learn from expert @rajivjalan.bsky.social about how to manage financial conflicts of interest #COI Today at #EASLCongress as part of a #YoungInvestigator Seminar! 📍 Erlinger Room 📅 Thurs, May 8 ⏲️ 15:35 - 15:45 h

📣 Today: #POSTER TOP-203, congrats 🥳 A rising international star is A-TANGO #YoungInvestigator Wenting Tan, UCL 👉 Recombinant insulin-like growth factor-1 #IGF1: a novel therapy for #patients with #cirrhosis + #ACLF 👉 Topic: Cirrhosis & Complications #LiverFailure #ACLF @rajivjalan.bsky.social

📣 Another top-notch #poster at the very heart of A-TANGO is THU-180-YI by Supachaya Sriphoosanaphan, UCL 👉 #TLR4 inhibition restores cytochrome C oxidase mitigating #hyperammonemia-induced hepatocyte mitochondrial dysfunction #Cirrhosis & Complications #ACLF #LiverFailure @rajivjalan.bsky.social

📣 Two fantastic #posters today - visit them before 5 pm! Both by Supachaya Sriphoosanaphan, UCL 👉 THU-182 Transcriptomic and metabolic insights into #hyperammonemia: the complementary therapeutic roles of #TLR4 inhibitor and ornithine phenylacetate 👉 #Cirrhosis & Complications #ACLF #LiverFailure

TODAY - catering provided🍎🥂 - just come by - still spots open, no registration needed ✅ A-TANGO #Investigator & #Industry Session 👉 Thurs, 8 May 👉 5-7 pm at #EASLCongress 🚨 Important: Access Room D202, Elicium Building (level 2), via bridge from main level #ACLF #cirrhosis #LiverFailure #GTAK

🎙️ Talking #ACLF with #patients! The A-TANGO Layman Event at #EASL2025 hit the sweet spot between science & lived experience 🧪 New solutions via the combinatorial G-TAK therapy are on the horizon to achieve the best possible care for #LiverPatients @europeliver.bsky.social @rajivjalan.bsky.social

🌍 Equity in liver care starts with #listening👂. At the #Patient & Advocate Forum during #EASL2025, Minneke Coenraad (LUMC) opened with a powerful message on addressing #healthcare #disparities in the Netherlands 🇳🇱. 👏 A timely reminder that innovation isn't only scientific - it's also social. 🥰

🤝 We’re live at the EF CLIF Networking Session at #EASL2025! Partners and collaborators are gathering to exchange insights on cirrhosis and its complications, building bridges between research and clinical innovation. 📍 Cirrhosis & Complications Track Hub @easlnews.bsky.social

👏 Our superstar Julian Pohl (Charité) is not only active in ACLF research but also brings 🧪 #suPAR & #MASLD into the spotlight! His poster WED-437 at #EASLCongress this year shows it can identify at-risk patients - a game-changer for non-invasive #diagnostics. #LiverDisease #biomarkers #metabolism

🤩 We are already in full #EASLCongress swing 🤩 here in Amsterdam, gearing up for 👉 the MICROB-PREDICT #NetworkingSession at the Cirrhosis & Complications Track Hub 4 at 14:00 👉 the simultaneous A-TANGO #PatientEvent from 14:00-15:00, Room D202 (level 2, Elicium Building) @easlnews.bsky.social

Have a glimpse at Wednesday's A-TANGO highlights at #EASLCongress in Amsterdam! 🤩 #ACLF #cirrhosis #PatientAdvocacy #PatientEvent #hepatology #GTAK #CombinatorialTherapy #MASLD #HealthcareDisparities @europeliver.bsky.social @easlnews.bsky.social @rajivjalan.bsky.social @korenjak.bsky.social

Last chance to register: docs.google.com/forms/d/e/1F... Don't miss out 😊. It also includes an 👉 Expert Panel: What have we learned about acute-on-chronic #LiverFailure #ACLF at #EASLCongress 2025 @easlnews.bsky.social @europeliver.bsky.social @decision4liver.bsky.social #LiverSky #cirrhosis

Feel free to follow the new A-TANGO Consortium + #hepatology Starter Pack go.bsky.app/Tc8YSWq #LiverSky #LiverResearch #LiverDisease #hepatitis #cirrhosis #ACLF #HepatologyJournals @rajivjalan.bsky.social @europeliver.bsky.social @easlnews.bsky.social @jhepatology.bsky.social @ebtapper.bsky.social

🚨 New Insights in Cirrhosis! 🚨 www.journal-of-hepatology.eu/article/S016... Our study reveals Non-Acute Decompensation (NAD) is a distinct clinical state, different from compensated cirrhosis & acute decompensation (AD) @rajivjalan.bsky.social @jhepatology.bsky.social @akashroyy.bsky.social

This #WorldLiverDay, honor the organ that filters, heals & protects. Say YES to fresh food, NO to harmful habits. Eat whole, live well. Your liver deserves better — and so do you. #FoodIsMedicine #LoveYourLiver #LiverHealthMatter @easlnews.bsky.social @korenjak.bsky.social @jvlazarus.bsky.social

Hope for #ACLF patients is on the horizon! Join the A-TANGO Patient Event at #EASLCongress: 📅 Wed, 7 May 2025 🕑 14:00–15:00 📍 Room D202, Elicium Building, Level 2 Learn about A-TANGO, the G-TAK trial and join the discussion on improving #patient outcomes. #LiverDisease @europeliver.bsky.social

Let’s talk #inflammation, #alcohol-related #hepatitis and new treatment strategies at #EASLCongress 👉 A-TANGO Networking Session 🗓️ Sat, 10 May 2025, 9:45–10:15 📍 Cirrhosis & Complications Track Hub These short networking sessions are lots of fun! @easlnews.bsky.social #hepatology #cirrhosis #ACLF

👉 Please register now: docs.google.com/forms/d/e/1F... Join us for the A-TANGO #Investigator & #Industry Session on Thursday, 8 May, from 5-7 pm at #EASLCongress. You can participate in person or online (Zoom Link will be set via email). #cirrhosis #LiverFailure #GTAK ✔️ Food & drinks provided 🥂

Just out: MICROB-PREDICT members have contributed to the newly published EASL #ClinicalPracticeGuidelines (CPG) on #TIPS, a procedure to address complications of #cirrhosis patients suffering from #PortalHypertension 👉 www.journal-of-hepatology.eu/article/S016... (DOI: 10.1016/j.jhep.2025.01.029)

👏 Whohoo! More than 300 experts from 140 organisations in 38 countries have joined the Liver Health Helix. Launched in 2021 to support A-TANGO's dissemination and impact, it is a community of #hepatology #LiverDisease #cirrhosis & #bioinformatics specialists. Join now: platform.crowdhelix.com/login

🩺 Who conducted the 1st #ClinicalTrial can be debated, but historical records suggest it happened in biblical times. Cornelius Engelmann (Charité), who supervises A-TANGO's clinical #GTAK trial, held an all-encompassing #Masterclass on Wed, 26 March 2025. #LiverFailure #ACLF #CombinatorialTherapy

📣 Welcome Troels Jordansen as the new CEO of Yaqrit! With over 30 years of international experience in pharmaceuticals, medical devices, cellular therapy, and biotech, Troels has a strong background in #sales, #marketing, #InvestorRelations, and #BusinessDevelopment. 💪 📰 yaqrit.com/_WPY2025/wp-...

📽️: youtu.be/7rnM-Cgl33U?... Watch our YouTube video with A-TANGO early-career scientists (ECS) Annarein Kerbert (MD, PhD) & Julian Pohl (MD) about #alcohol-related #LiverFailure vs. #infection-induced #ACLF at #EASLCongress 2024 #liversky @easlnews.bsky.social @ec.europa.eu @ebtapper.bsky.social

☺️ Welcome! 😊 You can now also follow us here on Bluesky. Spearheaded by EF CLIF, 13 partners joined forces for the A-TANGO project in March 2021 to develop G-TAK, a novel combinatorial therapy for #ACLF (acute-on-chronic #LiverFailure) by using the synergistic actions of G-CSF + TAK-242. #LiverSky